What does this research mean for the field?

GPR37 acts as a negative regulator of remyelination in the adult brain, and its absence enhances recovery across multiple distinct demyelinating disease models. Novelty: ClaimNovelty.NOVEL_FINDING. Consensus alignment: ConsensusAlignment.NEUTRAL.

What question did this study set out to answer?

This research aims to clarify how GPR37 affects recovery post-demyelination.

June 18, 2026Journal of Neuroscience

GPR37 modulates remyelination following demyelinating injury

View Full Paper

Ask AI

Bookmark

Authors

RKRenana Hajbi Karasik AVAnna Vainshtein RARina Aharoni

Discussion

Member takes

Overview

Randomized trial examines GPR37's effect on remyelination in mice, suggesting it may be a target for treatment.

Key Points

This research aims to clarify how GPR37 affects recovery post-demyelination.
Compared wild-type and GPR37-deficient mice after focal and global demyelination using lysolecithin and cuprizone, respectively.
Assessed immune-mediated demyelination via experimental autoimmune encephalomyelitis (EAE).
Measured recovery outcomes through lesion size and clinical scores.
Absence of GPR37 led to larger remyelinated areas and smaller lesions in focal demyelination models.
In the cuprizone model, GPR37-deficient mice exhibited faster and more extensive remyelination than wild-type.
Clinical scores of GPR37 null mice post-EAE were significantly lower than those of wild-type mice, indicating faster recovery.

Cite This Study

Karasik et al. (2026) studied this question.

synapsesocial.com/papers/6a338b7a630953a74978d166 https://doi.org/10.1523/jneurosci.0298-26.2026

View Full Paper

Ask AI

Bookmark

June 18, 2026Journal of Neuroscience

GPR37 modulates remyelination following demyelinating injury

View Full Paper

Ask AI

Bookmark

Authors

RKRenana Hajbi Karasik AVAnna Vainshtein RARina Aharoni

Discussion

Member takes

Overview

Randomized trial examines GPR37's effect on remyelination in mice, suggesting it may be a target for treatment.

Key Points

This research aims to clarify how GPR37 affects recovery post-demyelination.
Compared wild-type and GPR37-deficient mice after focal and global demyelination using lysolecithin and cuprizone, respectively.
Assessed immune-mediated demyelination via experimental autoimmune encephalomyelitis (EAE).
Measured recovery outcomes through lesion size and clinical scores.
Absence of GPR37 led to larger remyelinated areas and smaller lesions in focal demyelination models.
In the cuprizone model, GPR37-deficient mice exhibited faster and more extensive remyelination than wild-type.
Clinical scores of GPR37 null mice post-EAE were significantly lower than those of wild-type mice, indicating faster recovery.

Cite This Study

Karasik et al. (2026) studied this question.

synapsesocial.com/papers/6a338b7a630953a74978d166 https://doi.org/10.1523/jneurosci.0298-26.2026

View Full Paper

Ask AI

Bookmark